Health & Biotech
Orthocell soars 14% after crushing early sales growth for Remplir
Health & Biotech
Island completes phase 2b enrolments in dengue fever trial
Health & Biotech
Health Check: We’ll see you in court and you bladder believe it, says Pacific Edge after unfavourable US ruling
Health & Biotech
Biocurious: EZZ’s tennis sponsorship serves up 300 million Chinese viewers
Health & Biotech
Health tech Thrive Tribe serves up a new star chief exec
Health & Biotech
Recce Pharmaceuticals doses all patients in phase II skin infection trial
Health & Biotech
Health Check: Did the earth move for you? The world shifts on its axis as it enters the Trump era mark two
Health & Biotech
Dr Boreham’s Crucible: Radiopharm hopes to turn up the sweet sound of success
Health & Biotech
EBR’s US heart lead hopes tick up after wireless device gets nod for fast-track reimbursement pathway
Health & Biotech
Health Check: Investor hearts pump as EBR girds for US approval of novel pacemaker leads
Health & Biotech
Singular Health Group fulfils Phase 1 of US remote medical image aggregation MOU with PNS
Health & Biotech
Scott Power: Telix achieves sustained growth; Pro Medicus wins another contract
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.